Capricor Therapeutics, Inc. (CAPR), Friday announced positive three-year data from its ongoing HOPE-2 open label extension study of Deramiocel, for the treatment of Duchenne muscular dystrophy, a genetic disorder.
Presented at the 29th Annual Congress of the World Muscle Society, the data showed sustained cardiac and skeletal benefits after 3 years of continuous treatment with deramiocel.
Moreover, the participants demonstrated a statistically and clinically relevant benefit in the total score of PUL v2.0, a scale wthat grades the performance of multiple functional skills, when compared to an external comparator dataset.
The biotechnology company added that the study continues to show a favorable safety profile for long-term treatment of Deramiocel.
Currently, Capricor's stock is moving up 9.31 percent, to $18.71 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.